Terns Pharmaceuticals, INC 8-K filings

Merck has successfully acquired Terns Pharmaceuticals in a tender offer and subsequent merger, with Terns now operating as a wholly owned subsidiary.

Terns Pharmaceuticals announced its drug candidate TERN-701 has received FDA Breakthrough Therapy Designation for treating chronic myeloid leukemia.

Merck announced a definitive agreement to acquire Terns Pharmaceuticals for $53.00 per share in cash, valuing the company at approximately $6.7 billion.

Terns Pharmaceuticals amended its agreement with Hansoh, gaining exclusive worldwide rights to TERN-701 outside the Hansoh Territory for a $1 million upfront fee and tiered royalties.

Terns Pharmaceuticals announced its 2026 priorities and program milestones for TERN-701, alongside a robust unaudited cash position of approximately $1.0 billion extending into 2031.

Terns Pharmaceuticals announced the pricing of an upsized underwritten public offering of common stock, expected to generate approximately $705.8 million in net proceeds to fund its pipeline and extend its cash runway into 2031.

Terns Pharmaceuticals announced updated positive Phase 1 CARDINAL trial data for TERN-701 in previously treated chronic myeloid leukemia patients at the 67th ASH Annual Meeting.

Terns Pharmaceuticals reported Q3 2025 financial results, showcasing strong Phase 1 CML data for TERN-701 and a strategic pivot away from metabolic disease programs.

Terns Pharmaceuticals announced positive Phase 1 CARDINAL trial data for TERN-701 in relapsed/refractory CML, showing high major molecular response rates and an encouraging safety profile.

Terns Pharmaceuticals announced disappointing topline 12-week Phase 2 results for its oral GLP-1 receptor agonist TERN-601, leading to the discontinuation of its obesity program.

Terns Pharmaceuticals reported Q2 2025 financial results, highlighting progress in its CML and obesity clinical programs with key data readouts expected in Q4 2025 and a cash runway into 2028.

Terns Pharmaceuticals, Inc. announced the successful election of three Class I directors and the ratification of Ernst & Young LLP as its independent auditor at its 2025 Annual Meeting of Stockholders.

Terns Pharmaceuticals announces its Q1 2025 financial results, highlighting progress in its clinical programs for CML and obesity, with key data readouts expected in Q4 2025.

Terns Pharmaceuticals reports positive financial results for 2024, highlighted by clinical progress in TERN-701 and TERN-601 trials, and anticipates key data readouts in 2025.

Terns Pharmaceuticals appoints Andrew Gengos as its new Chief Financial Officer, effective February 24, 2025.

Terns Pharmaceuticals appoints Robert Azelby to its Board of Directors, effective immediately, while Carl Gordon steps down after seven years of service.

Terns Pharmaceuticals announces the departure of CFO Mark Vignola, Ph.D., effective February 1, 2025, and the appointment of interim replacements.

Terns Pharmaceuticals reported encouraging early results from its Phase 1 CARDINAL study of TERN-701, showing significant molecular responses and a favorable safety profile in patients with relapsed/refractory chronic myeloid leukemia.

Terns Pharmaceuticals has appointed Heather Turner as a new board member, effective November 18, 2024, following the resignation of Ann Taylor.

Terns Pharmaceuticals announced positive Phase 1 results for its obesity drug TERN-601, plans for a Phase 2 trial, and a successful equity raise extending its cash runway into 2028.

Terns Pharmaceuticals has announced the pricing of an upsized public offering expected to generate approximately $150.15 million in gross proceeds.

Terns Pharmaceuticals reports positive top-line data from its Phase 1 trial of TERN-601, showing significant weight loss and good tolerability in obese and overweight adults.

Terns Pharmaceuticals reported its second quarter 2024 financial results, highlighted by upcoming clinical trial data readouts and a cash runway extending into 2026.

Terns Pharmaceuticals has appointed Elona Kogan as Chief Legal Officer and announced the planned departures of the Chief Financial Officer and Chief Operating Officer.

Terns Pharmaceuticals has extended its office lease in Foster City for an additional 36 months, with an option for a further three-year extension.

Terns Pharmaceuticals held its 2024 Annual Meeting of Stockholders, electing two Class III directors and ratifying Ernst & Young LLP as its independent auditor for the fiscal year ending December 31, 2024.

Terns Pharmaceuticals announced its first quarter 2024 financial results, highlighting progress in its clinical programs and a cash runway into 2026.

Terns Pharmaceuticals reports promising Phase 1 pharmacokinetic data for TERN-701, showing it can be dosed without regard to food, a potential advantage over existing treatments for chronic myeloid leukemia (CML).

Terns Pharmaceuticals announced its 2023 financial results, highlighted by a $263 million cash position and progress in clinical trials for its oncology and obesity programs.

Terns Pharmaceuticals has appointed Amy Burroughs as its new Chief Executive Officer and a member of the Board of Directors, effective February 7, 2024.